![Full Text of PDF](img/ico_pdf_full.gif)
Article in Japanese
Three cases of multicentric Castleman disease with pulmonary involvement treated with tocilizumab
Shinobu Tamuraa,b Hideki Kosakob Yoshikazu Horib Masaya Morimotob Toshiki Mushinoa,b Takashi Sonokia
aDepartment of Hematology/Oncology, Wakayama Medical University
bDepartment of Hematology, Kinan Hospital
We experienced three cases of multicentric Castleman disease (MCD) with pulmonary involvement treated with tocilizumab. These cases consisted of two males and one female, and average age at the first visit was 44 years. Lymph node biopsy led to all cases being diagnosed as MCD, plasma cell type. Chest computed tomography (CT) revealed multiple bilateral interstitial shadows. On diagnosis, we selected watchful waiting in two cases and prednisolone therapy in one case. However, due to worsening pulmonary shadows and respiratory symptoms, all cases were started on tocilizumab therapy. After this therapy, although the respiratory symptoms soon disappeared, partial interstitial shadows remained. Our cases suggest early intervention of tocilizumab therapy for MCD with pulmonary involvement.
Multicentric Castleman disease Pulmonary involvement Tocilizumab
Received 20 Nov 2019 / Accepted 8 Jan 2020
AJRS, 9(3): 211-216, 2020